PT - JOURNAL ARTICLE AU - Kishimoto, Taishiro AU - Kinoshita, Shotaro AU - Bun, Shogyoku AU - Sato, Yasunori AU - Kitazawa, Momoko AU - Kikuchi, Toshiaki AU - Sado, Mitsuhiro AU - Takamiya, Akihiro AU - Mimura, Masaru AU - Nakamae, Takashi AU - Abe, Yoshinari AU - Kanazawa, Tetsufumi AU - Kawabata, Yasuo AU - Tomita, Hiroaki AU - Abe, Koichi AU - Hishimoto, Akitoyo AU - Asami, Takeshi AU - Suda, Akira AU - Watanabe, Yoshinori AU - Amagai, Toru AU - Sakuma, Kei AU - Kida, Hisashi AU - Funayama, Michitaka AU - Kimura, Hiroshi AU - Sato, Aiko AU - Fujiwara, Shuichiro AU - Nagao, Kiichiro AU - Sugiyama, Naoya AU - Takamiya, Maki AU - Kodama, Hideyuki AU - Azekawa, Takaharu AU - on behalf of the J-PROTECT collaborators TI - Japanese Project for Telepsychiatry Evaluation during COVID-19: Treatment Comparison Trial (J-PROTECT): Rationale, design, and methodology AID - 10.1101/2021.06.23.21259366 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.23.21259366 4099 - http://medrxiv.org/content/early/2021/06/29/2021.06.23.21259366.short 4100 - http://medrxiv.org/content/early/2021/06/29/2021.06.23.21259366.full AB - Introduction The COVID-19 pandemic has had a profound impact on the mental health of people around the world. Anxiety related to infection, stress and stigma caused by the forced changes in daily life have reportedly increased the incidence and symptoms of depression, anxiety disorder and obsessive-compulsive disorder. Under such circumstances, telepsychiatry is gaining importance and attracting a great deal of attention. However, few large pragmatic clinical trials on the use of telepsychiatry targeting multiple psychiatric disorders have been conducted to date.Methods The targeted study cohort will consist of adults (>18 years) who meet the DSM-5 diagnostic criteria for either (1) depressive disorders, (2) anxiety disorders, or (3) obsessive-compulsive and related disorders. Patients will be assigned in a 1:1 ratio to either a “telepsychiatry group” (at least 50% of visits to be conducted using telemedicine, with at least one face-to-face treatment [FTF] every six months) or an “FTF group” (all visits to be conducted FTF, with no telemedicine). Both groups will receive the usual treatment covered by public medical insurance. The study will utilize a master protocol design in that there will be primary and secondary outcomes for the entire group regardless of diagnosis, as well as the outcomes for each individual disorder group.Discussion This study will be a non-inferiority trial to test that the treatment effect of telepsychiatry is not inferior to that of FTF alone. This study will provide useful insights into the effect of the COVID-19 pandemic on the practice of psychiatry.Trial Registration jRCT1030210037, Japan Registry of Clinical Trials (jRCT)Competing Interest StatementT. Kishimoto: Research grant funding, Micin.T. Nakamae: Provided with a telemedicine system, Medley.Y. Abe: Provided with a telemedicine system, Medley.Clinical TrialjRCT1030210037Funding StatementThis research is supported by the Japan Agency for Medical Research and Development (AMED) under Grant Number JP21dk0307098.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board of the National Center of Neurology and Psychiatry and the participating medical facilities.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to the nature of this research, participants of this study did not agree for their data to be shared publicly, so supporting data is not available.COVID-19the 2019 novel coronavirus diseaseJ-PROTECTJapanese Project for Telepsychiatry Evaluation during COVID-19: Treatment Comparison TrialDSM-5Diagnostic and Statistical Manual of Mental Disorders, Fifth EditionFTFface-to-face treatmentjRCTJapan Registry of Clinical TrialsOCDobsessive–compulsive disorderSF36MCSMOS36-Item Short-Form Health Survey Mental Component SummarySF36MOS 36-Item Short-Form Health SurveyWAIWorking Alliance InventoryCSQClient Satisfaction QuestionnaireEQ-5DEuroQol 5 DimensionHAMDHamilton Depression Rating ScaleHAMAHamilton Anxiety Rating ScaleYBOCSYale-Brown Obsessive Compulsive ScaleEDCelectronic data captureePROelectronic patient-reported outcomeQOLquality of life